GlassScriptPhysician profile
Timothy J Ansley
NPI 1326447822
$11,999.99
in general payments reported to CMS, 2019-2025
26 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,773 · 2020: $1,225 · 2021: $1,135 · 2022: $1,892 · 2023: $1,667 · 2024: $2,902 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,948 · Entertainment: $1,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,948.40 |
| Entertainment | $1,025.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,066.14 | 2019-2025 | Precision7, Total30, Precision 1 |
| Optos, INC. | $1,550.32 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $1,511.82 | 2022-2025 | Infuse, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,504.60 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $964.78 | 2019-2025 | Acuvue |
| Topcon Healthcare, INC. | $930.26 | 2024 | |
| Biotissue Holdings INC. | $929.66 | 2022-2025 | |
| Coopervision INC. | $888.79 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Sun Pharmaceutical Industries INC. | $502.66 | 2019-2022 | |
| Allergan, INC. | $278.07 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $176.98 | 2019-2021 | |
| New World Medical,INC. | $129.51 | 2022 | |
| Oyster Point Pharma, INC. | $125.57 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $75.40 | 2024-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $66.53 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $59.43 | 2024-2025 | Xdemvy |
| Carl Zeiss Meditec USA, INC. | $40.61 | 2024-2025 | Cirrus Hd-Oct |
| Harrow Eye, LLC | $32.21 | 2025 | Vevye |
| Maculogix, INC. | $29.73 | 2021 | |
| Mallinckrodt Hospital Products INC. | $26.35 | 2023 | Acthar |
| Ocular Therapeutix, INC. | $22.74 | 2024 | Dextenza |
| Abbvie INC. | $20.81 | 2022 | |
| Thea Pharma INC. | $18.33 | 2022 | |
| Alcon Research LLC | $17.27 | 2019 | |
| Aerie Pharmaceuticals, INC. | $16.96 | 2021 | |
| Shire North American Group INC | $14.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Ansley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.